• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Certara Inc.

    4/12/24 4:15:26 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    DEFA14A 1 tm242785d7_defa14a.htm DEFA14A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the 

    Securities Exchange Act of 1934 

    (Amendment No.            )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    x Definitive Additional Materials

     

    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Certara, Inc. 

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

      x No fee required.

     

      ¨ Fee paid previously with preliminary materials.
         
      ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

     

     

     

     

    Explanatory Note

     

    This supplement (the “Supplement”) amends and supplements the definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed by Certara, Inc. (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2024, in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Tuesday, May 21, 2024, at 9:00 a.m. Eastern Time.

     

    The purpose of this Supplement is to correct an inadvertent error in the Proxy Statement regarding the treatment of abstention and effect of broker non-votes on Proposals 2A and 2B — Approval of Amendments to our Amended and Restated Certificate of Incorporation, as well as to incorporate additional clarifying changes.

     

    The correction to the existing disclosure in the Proxy Statement is set forth below under the heading “Revisions to the Proxy Statement.” Capitalized terms not defined in this Supplement have the terms set forth in the Proxy Statement. Other than as set forth below, no other changes have been made to the Proxy Statement and it continues to be in full force and effect as originally filed with the SEC and the Board of Directors of the Company continues to seek the vote of Company stockholders on each of the proposals to be voted on at the Annual Meeting as recommended in the original filing. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as amended and supplemented by this Supplement. This Supplement should be read in conjunction with the Proxy Statement and the other proxy materials previously made available to stockholders in connection with the Annual Meeting. If you have already voted your shares, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal.

     

    Revisions to the Proxy Statement

     

    The answer to the question entitled, “What are the voting requirements to approve each of the proposals?” in the Annual Meeting Information section of the Proxy Statement is amended and restated in its entirety to read as follows (corrections and clarifications are marked, with new text underlined, and deleted text stricken through):

     

    What are the voting requirements to approve each of the proposals?

     

    ​ PROPOSALS     VOTE REQUIRED     BROKER
    DISCRETIONARY
    VOTING ALLOWED
    ​
      1     Election of Class I directors.     Plurality of votes cast for each director nominee (the nominees receiving the most “FOR” votes)     No  
      2a and 2b    

    To approve two separate proposals to amend our Certificate of Incorporation:

    a.   Amend our Certificate of Incorporation to limit the liability of certain officers of Certara as permitted pursuant to the Delaware General Corporation Law; and

    b.   Amend our Certificate of Incorporation to make certain technical changes, including to remove inoperative provisions related to our former majority stockholder and other immaterial changes.

        The affirmative vote of the holders of at least 66⅔% in voting power of all the then outstanding shares of capital stock of the Company entitled to vote thereon, voting together as a single class     No  
      3     Ratification of the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024.     Majority of the voting power of the shares of stock present in person or represented by proxy and entitled to vote on the matter     Yes  
      4     To conduct a non-binding advisory vote to approve the compensation of our named executive officers.     Majority of the voting power of the shares of stock present in person or represented by proxy and entitled to vote on the matter     No  

     

     

     

     

    With respect to Proposal 1 (Election of Class I Directors), you may vote “For” or “Withhold” with respect to each director nominee. Only votes cast “For” a nominee will be counted in the election of directors. Votes cast to “Withhold” with respect to one or more nominees will result in those nominees receiving fewer votes but will not count as a vote against the nominees. The individuals who receive the highest number of votes are elected as directors up to the maximum number of directors to be elected at the meeting. This means that once a quorum is established, the three nominees receiving the highest number of votes at the annual meeting will be elected, even if these votes do not constitute a majority of the votes cast. Proxies may not be voted for more than three directors and stockholders may not cumulate votes in the election of directors. Votes that are “Withheld” with respect to one or more nominees will result in those nominees receiving fewer votes but will not count as a vote “Against” the nominees.

     

    With respect to Proposals 2a and 2b (Approval of amendments to our Amended and Restated Certificate of Incorporation to (a) to limit the liability of certain officers of Certara as permitted pursuant to the Delaware General Corporation Law and (b) to make certain technical changes, including to remove inoperative provisions related to our former majority stockholder and other immaterial changes ), you may vote “For,” “Against,” or “Abstain.” The affirmative vote of the holders of at least 66 2/3% in voting power of all the then outstanding shares of capital stock of the Company entitled to vote thereon, voting together as a single class. Abstentions and broker non-votes will have the same effect as votes “Against” Proposals 2a and 2b.

     

    With respect to Proposal 3 (Ratification of the appointment of independent registered public accounting firm for the fiscal year ending December 31, 2024), you may vote “For,” “Against,” or “Abstain.” If you abstain from voting on this matter, your shares will be counted as present and entitled to vote on that matter for purposes of establishing a quorum but will not be counted for purposes of determining the number of votes cast. Abstentions will have the same effect as a vote “Against” this proposal. Proposal 3 is the only proposal on which your broker is entitled to vote your shares if no instructions are received from you. Because Proposal 3 is “routine,” we do not expect that any broker non-votes will occur with respect to such proposal.

     

    With respect to Proposal 4 (A non-binding advisory vote to approve the compensation of our named executive officers), you may vote for “For,” “Against,” or “Abstain.” This proposal requires the favorable vote of the holders of a majority of the voting power of the shares of common stock present in person or represented by proxy at the annual meeting and entitled to vote on the proposal. Abstentions will have the same effect as a vote “Against” this proposal. Because broker non-votes do not count as shares entitled to vote, they will not affect the outcome of the vote on this proposal.

     

    Abstentions will not affect the outcome of Proposals 1, 2a, 2b, 3, or 4 because abstentions are not considered votes cast on those proposals. For additional information regarding the impact of the foregoing on the determination of a quorum for the Annual Meeting, please see “How is a quorum determined?” above.

     

     

     

    Get the next $CERT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    1/6/2026$13.00Market Perform → Outperform
    Leerink Partners
    11/21/2025$10.00Buy
    Rothschild & Co Redburn
    11/13/2025$9.00Market Perform
    BMO Capital Markets
    9/29/2025$16.00Buy
    Craig Hallum
    7/3/2025$16.00Equal-Weight
    Morgan Stanley
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    More analyst ratings

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Resnick Jon Matthew

    3 - Certara, Inc. (0001827090) (Issuer)

    1/12/26 4:59:18 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E sold $559,366 worth of shares (51,224 units at $10.92), decreasing direct ownership by 41% to 73,979 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    9/11/25 4:47:56 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Certara upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Certara from Market Perform to Outperform and set a new price target of $13.00

    1/6/26 8:38:03 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Rothschild & Co Redburn initiated coverage on Certara with a new price target

    Rothschild & Co Redburn initiated coverage of Certara with a rating of Buy and set a new price target of $10.00

    11/21/25 8:08:25 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    BMO Capital Markets initiated coverage on Certara with a new price target

    BMO Capital Markets initiated coverage of Certara with a rating of Market Perform and set a new price target of $9.00

    11/13/25 9:12:36 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    SEC Filings

    View All

    Certara Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Certara, Inc. (0001827090) (Filer)

    12/11/25 6:00:54 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

    SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)

    11/25/25 3:36:45 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13G filed by Certara Inc.

    SCHEDULE 13G - Certara, Inc. (0001827090) (Subject)

    11/13/25 5:32:49 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

    RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic

    1/29/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave

    Issued on behalf of Aleen Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approaches to computational creation of biological solutions[1]. The generative AI healthcare market is projected to surge from $2.64B in 2025 to $39.70B by 2034, reflecting the technology's expansion from simple data analysis to active creation and interpretation of therapeutic compounds[2]. This Platform-First revolution is extending rapidly into c

    12/12/25 10:15:00 AM ET
    $ABSI
    $AMZN
    $CERT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary

    Healthcare AI Exits Pilot Phase, Enters Production Deployment

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns

    12/12/25 9:59:27 AM ET
    $CERT
    $CTSH
    $DOCS
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Medical Specialities

    $CERT
    Leadership Updates

    Live Leadership Updates

    View All

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

    RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data

    7/31/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

    RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President of Drug Development Solutions, effective March 3rd, 2025. In this role, McKemey will lead Certara's global team of drug development scientists. Adrian joins Certara after serving as head of Enterprise Transformation at IQVIA and Senior Vice President and Head of the R&D Strategy Solutions at Quintiles. He has over 25 years of experience in research and development roles where he focused on business transformation, portfolio management and R&D strategies. Before IQVIA, he was a Principal with t

    3/5/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Financials

    Live finance-specific insights

    View All

    Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

    RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medic

    1/29/26 8:30:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports Third Quarter 2025 Financial Results

    RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 million, compared to $58.9 million in the third quarter of 2024, representing growth of 3%. Net income was $1.5 million, compared to a net loss of $1.4 million in the third quarter of 2024, representing

    11/6/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

    RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulation softw

    10/10/25 8:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Certara Inc.

    SC 13G - Certara, Inc. (0001827090) (Subject)

    11/14/24 8:38:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Certara Inc.

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    10/4/24 10:25:50 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology